Information Provided By:
Fly News Breaks for February 13, 2020
Feb 13, 2020 | 07:24 EDT
Credit Suisse analyst Martin Auster raised his price target for United Therapeutics to $121 from $113 as he has grown increasingly constructive on the name into 2020, owing to the continued resilience of Remodulin despite about 1 year of generic competition. His channel checks continue to suggest a gradual uptake of IV generic treprostinil, and recent management comments support a bullish outlook for the franchise. He has an Outperform rating on the shares.
News For UTHR From the Last 2 Days
There are no results for your query UTHR